ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

SA Transcripts 161.45K Followers Follow ClearPoint Neuro, Inc. ( CLPT ) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDT Company Participants Joseph Burnett - President, CEO & Director Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Mathew Blackman - TD Cowen, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Presentation Operator Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, the company's plans, prospects and strategies and its beliefs, estimates or projections regarding future revenue and results of operations. You are cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they are made. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for the new information or future events except as required by law. For more information about the company's risks and uncertainties, please refer to the company's filings with the SEC, including the company's recent filings on Form 8-K, Form 10-K and Form 10-Q. All the company's filings may be obtained from the SEC or the company's website at www.clearpointneuro.com. And now I'll turn the call over to Joe Burnett, Chief Executive Officer. Thank you. You may begin. Joseph Burnett President, CEO & Director Thank you. And as always, thank you to all the investors, analysts, and biopharma partners listening to today's call. We remain both committed to and focused on developing a complete neuro ecosystem capable of delivering various minimally invasive treatments, including cell and gene therapies to the brain. We believe that this approach will finally unlock hope for the patients and their families who are battling these frightening neurologic disorders and who today have very